Jiangsu Hengrui Medicine Co., Ltd.
https://www.hrs.com.cn/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jiangsu Hengrui Medicine Co., Ltd.
US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics
Five novel agents are among the user fee goal dates coming up in May 2024.
AstraZeneca’s Next-Gen PARP Inhibitor Hints At Better Safety And Efficacy In Breast Cancer
Early signs of improved safety and efficacy should set up PARP1 inhibitor for potential combinations and future broader use, but the true extent of its benefits remain to be seen.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Merck KGaA Looks To Build Cancer ADCs With Caris’s AI Technology
Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Atridia Pty Ltd
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice